P. Kelly Marcom

18.1k total citations · 5 hit papers
98 papers, 8.1k citations indexed

About

P. Kelly Marcom is a scholar working on Oncology, Cancer Research and Genetics. According to data from OpenAlex, P. Kelly Marcom has authored 98 papers receiving a total of 8.1k indexed citations (citations by other indexed papers that have themselves been cited), including 57 papers in Oncology, 38 papers in Cancer Research and 26 papers in Genetics. Recurrent topics in P. Kelly Marcom's work include Breast Cancer Treatment Studies (31 papers), BRCA gene mutations in cancer (20 papers) and HER2/EGFR in Cancer Research (20 papers). P. Kelly Marcom is often cited by papers focused on Breast Cancer Treatment Studies (31 papers), BRCA gene mutations in cancer (20 papers) and HER2/EGFR in Cancer Research (20 papers). P. Kelly Marcom collaborates with scholars based in United States, Singapore and United Kingdom. P. Kelly Marcom's co-authors include Kimberly Blackwell, Beth Overmoyer, Eric P. Winer, Hope S. Rugo, Matthew J. Ellis, Frankie A. Holmes, Kathy D. Miller, Louis Fehrenbacher, Melody Cobleigh and Amy P. Sing and has published in prestigious journals such as New England Journal of Medicine, Journal of Clinical Oncology and Cancer.

In The Last Decade

P. Kelly Marcom

97 papers receiving 7.9k citations

Hit Papers

Randomized Phase III Trial of Capecitabine Compared With ... 2005 2026 2012 2019 2005 2008 2011 2005 2015 250 500 750 1000
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Randomized Phase III Trial of Capecitabine Compared With Bevacizumab Plus Capecitabine in Patients With Previously Treated Metastatic Breast Cancer
    2005 1.0k citations P. Kelly Marcom, Beth Overmoyer et al. Journal of Clinical Oncology profile →
  2. Young Age at Diagnosis Correlates With Worse Prognosis and Defines a Subset of Breast Cancers With Shared Patterns of Gene Expression
    2008 646 citations Gloria Broadwater, P. Kelly Marcom et al. Journal of Clinical Oncology profile →
  3. Circulating Tumor Cells from Patients with Advanced Prostate and Breast Cancer Display Both Epithelial and Mesenchymal Markers
    2011 536 citations Andrew J. Armstrong, Matthew S. Marengo et al. Molecular Cancer Research profile →
  4. Phase I Safety, Pharmacokinetics, and Clinical Activity Study of Lapatinib (GW572016), a Reversible Dual Inhibitor of Epidermal Growth Factor Receptor Tyrosine Kinases, in Heavily Pretreated Patients With Metastatic Carcinomas
    2005 503 citations Howard A. Burris, Herbert I. Hurwitz et al. Journal of Clinical Oncology profile →
  5. Adjuvant Paclitaxel and Trastuzumab for Node-Negative, HER2-Positive Breast Cancer
    2015 458 citations William T. Barry, Beverly Moy et al. profile →

Peers

P. Kelly Marcom
Kimberly Blackwell United States
William T. Barry United States
Andreas du Bois Germany
Brian L. Sprague United States
Boštjan Šeruga Canada
Virginia F. Borges United States
Gabe S. Sonke Netherlands
Alastair M. Thompson United States
George Somlo United States
Amanda L. Blackford United States
Kimberly Blackwell United States
P. Kelly Marcom
Citations per year, relative to P. Kelly Marcom P. Kelly Marcom (= 1×) peers Kimberly Blackwell

Countries citing papers authored by P. Kelly Marcom

Since Specialization
Citations

This map shows the geographic impact of P. Kelly Marcom's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by P. Kelly Marcom with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites P. Kelly Marcom more than expected).

Fields of papers citing papers by P. Kelly Marcom

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by P. Kelly Marcom. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by P. Kelly Marcom. The network helps show where P. Kelly Marcom may publish in the future.

Co-authorship network of co-authors of P. Kelly Marcom

This figure shows the co-authorship network connecting the top 25 collaborators of P. Kelly Marcom. A scholar is included among the top collaborators of P. Kelly Marcom based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with P. Kelly Marcom. P. Kelly Marcom is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Smith, Claire E.P., P. Kelly Marcom, Zahi Mitri, & Naomi Y. Ko. (2022). Predictors of long-term durable response in de novo HER2-positive metastatic breast cancer and the real-world treatment experience at two institutions. Breast Cancer Research and Treatment. 196(1). 215–220. 4 indexed citations
2.
Paoletti, Costanza, Meredith M. Regan, Samuel M. Niman, et al.. (2021). Circulating tumor cell number and endocrine therapy index in ER positive metastatic breast cancer patients. npj Breast Cancer. 7(1). 77–77. 21 indexed citations
3.
Fayanju, Oluwadamilola M., Yi Ren, Madeline Thornton, et al.. (2020). Patient‐reported causes of distress predict disparities in time to evaluation and time to treatment after breast cancer diagnosis. Cancer. 127(5). 757–768. 31 indexed citations
4.
Fayanju, Oluwadamilola M., Yi Ren, Benjamin A. Goldstein, et al.. (2019). The effect of treatment on patient‐reported distress after breast cancer diagnosis. Cancer. 125(17). 3040–3049. 13 indexed citations
5.
Crosby, Erika J., William R. Gwin, Kimberly Blackwell, et al.. (2019). Vaccine-Induced Memory CD8+ T Cells Provide Clinical Benefit in HER2 Expressing Breast Cancer: A Mouse to Human Translational Study. Clinical Cancer Research. 25(9). 2725–2736. 54 indexed citations
6.
Havrilesky, Laura J., Evan R. Myers, Junzo Chino, et al.. (2017). Cost Effectiveness of Risk-Reducing Mastectomy versus Surveillance in BRCA Mutation Carriers with a History of Ovarian Cancer. Annals of Surgical Oncology. 24(11). 3116–3123. 15 indexed citations
7.
Kamal, Arif H., et al.. (2014). Optimizing the Quality of Breast Cancer Biomarker Use at Duke Cancer Institute. Journal of the National Comprehensive Cancer Network. 12(suppl 1). S–21. 3 indexed citations
8.
Hamilton, Erika, Gretchen Kimmick, Judith O. Hopkins, et al.. (2013). Nab-Paclitaxel/Bevacizumab/Carboplatin Chemotherapy in First-Line Triple Negative Metastatic Breast Cancer. Clinical Breast Cancer. 13(6). 416–420. 49 indexed citations
9.
10.
Armstrong, Andrew J., Matthew S. Marengo, Sebastian Oltean, et al.. (2011). Circulating Tumor Cells from Patients with Advanced Prostate and Breast Cancer Display Both Epithelial and Mesenchymal Markers. Molecular Cancer Research. 9(8). 997–1007. 536 indexed citations breakdown →
11.
Barry, William T., Dawn Kernagis, Holly K. Dressman, et al.. (2010). Intratumor Heterogeneity and Precision of Microarray-Based Predictors of Breast Cancer Biology and Clinical Outcome. Journal of Clinical Oncology. 28(13). 2198–2206. 84 indexed citations
12.
Zhai, Jun, Brian R. Untch, Matthew J. Ellis, et al.. (2009). Novel tumor sampling strategies to enable microarray gene expression signatures in breast cancer: a study to determine feasibility and reproducibility in the context of clinical care. Breast Cancer Research and Treatment. 118(3). 635–43. 7 indexed citations
13.
Olson, John A., Thomas Budd, Lisa A. Carey, et al.. (2009). Improved Surgical Outcomes for Breast Cancer Patients Receiving Neoadjuvant Aromatase Inhibitor Therapy: Results from a Multicenter Phase II Trial. Journal of the American College of Surgeons. 208(5). 906–914. 65 indexed citations
14.
Demark‐Wahnefried, Wendy, L. Douglas Case, Kimberly Blackwell, et al.. (2008). Results of a Diet/Exercise Feasibility Trial to Prevent Adverse Body Composition Change in Breast Cancer Patients on Adjuvant Chemotherapy. Clinical Breast Cancer. 8(1). 70–79. 131 indexed citations
15.
Lehman, Constance D., Claudine Isaacs, Mitchell D. Schnall, et al.. (2007). Cancer Yield of Mammography, MR, and US in High-Risk Women: Prospective Multi-Institution Breast Cancer Screening Study. Radiology. 244(2). 381–388. 288 indexed citations
16.
17.
Burris, Howard A., Herbert I. Hurwitz, Elizabeth Claire Dees, et al.. (2005). Phase I Safety, Pharmacokinetics, and Clinical Activity Study of Lapatinib (GW572016), a Reversible Dual Inhibitor of Epidermal Growth Factor Receptor Tyrosine Kinases, in Heavily Pretreated Patients With Metastatic Carcinomas. Journal of Clinical Oncology. 23(23). 5305–5313. 503 indexed citations breakdown →
18.
Spector, Neil L., Wenle Xia, Howard A. Burris, et al.. (2005). Study of the Biologic Effects of Lapatinib, a Reversible Inhibitor of ErbB1 and ErbB2 Tyrosine Kinases, on Tumor Growth and Survival Pathways in Patients With Advanced Malignancies. Journal of Clinical Oncology. 23(11). 2502–2512. 290 indexed citations
19.
Skinner, Celette Sugg, Joellen M. Schildkraut, Donald A. Berry, et al.. (2002). Pre-Counseling Education Materials for BRCA Testing: Does Tailoring Make a Difference?. Genetic Testing. 6(2). 93–105. 58 indexed citations
20.
Ortel, Thomas L., Linda Charles, Frank G. Keller, et al.. (1994). Topical thrombin and acquired coagulation factor inhibitors: Clinical spectrum and laboratory diagnosis. American Journal of Hematology. 45(2). 128–135. 96 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Kimberly Blackwell Breakdown of academic impact, for papers by William T. Barry Breakdown of academic impact, for papers by Andreas du Bois Breakdown of academic impact, for papers by Brian L. Sprague Breakdown of academic impact, for papers by Boštjan Šeruga Breakdown of academic impact, for papers by Virginia F. Borges Breakdown of academic impact, for papers by Gabe S. Sonke Breakdown of academic impact, for papers by Alastair M. Thompson Breakdown of academic impact, for papers by George Somlo Breakdown of academic impact, for papers by Amanda L. Blackford
Rankless by CCL
2026